SCHEMBL26964211

SCHEMBL26964211

Nc1cccc2c1CN(C1CC1)C2

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC18A3 Q16572 2/20 0.38
CD44 P16070 1/20 0.37
CTSD P07339 1/20 0.36
HRH3 Q9Y5N1 2/20 0.36
KCNH2 Q12809 2/20 0.36
DPP4 P27487 1/20 0.35
FAP Q12884 1/20 0.35
DPP8 Q6V1X1 1/20 0.35
DPP9 Q86TI2 1/20 0.35
DPP7 Q9UHL4 1/20 0.35
GRIN2B Q13224 1/20 0.34
SLC6A2 P23975 3/20 0.33
SLC6A4 P31645 3/20 0.33
SLC6A3 Q01959 3/20 0.33
RGS12 O14924 1/20 0.33
LMNA P02545 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
ALOX12 P18054 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11264347 0.78 ABCB1 (0.42) HRH3KCNH2DPP4FAPDPP8
SCHEMBL11265606 0.75 HRH3 (0.53) SLC18A3HRH3KCNH2DPP4FAP
SCHEMBL25773406 0.74 KCNH2 (0.33) HRH3KCNH2DPP4FAPDPP8
SCHEMBL25773312 0.74 CA2 (0.34) HRH3KCNH2DPP4FAPDPP8
SCHEMBL1426296 0.72 CRBN (0.70) CYP1A2OPRM1
SCHEMBL26964204 0.71 TDP1 (0.39) LMNACYP3A4MAPK1
SCHEMBL29800757 0.71 TDP1 (0.39) LMNACYP3A4MAPK1
SCHEMBL25297029 0.71 CRBN (0.38) SLC18A3CYP3A4MAPK1
SCHEMBL30496668 0.71 CRBN (0.38) SLC18A3CYP3A4MAPK1
SCHEMBL6785952 0.71 SLC6A2 (0.46) CD44KCNH2SLC6A2SLC6A4SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240148744-A1 SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES ZOETIS LLC 2024-05-09 US disclosed
EP-4291555-A1 SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES Celgene Corporation (US) 2023-12-20 EP disclosed
WO-2022173727-A1 SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES CELGENE CORPORATION (US) 2022-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240148744-A1 SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES ARSA, MRPS2, SULT2A1 SLC18A3 4688/4885CD44 2319/4885CTSD 1655/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.